Analysts expect Ligand Pharmaceuticals Inc to report revenue of 74.19 M for Q3 26, against a range of 67.25 M to 81.13 M. The most recent reported quarter, Q2 26, came in at 63.69 M, a 10.3% beat against the 57.73 M consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 51.81 M | 42.81 M | 45.33 M | 47.63 M | 115.46 M | 59.67 M | 51.72 M | 63.69 M | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 41.91 M | 40.54 M | 39.06 M | 47.16 M | 68.42 M | 61.14 M | 61.06 M | 62.68 M | 81.13 M | 98.56 M | 76.39 M | 85.81 M | 134.55 M | 129.49 M | 90.69 M | 99.82 M | ||||||||||
| Low Estimate | 35.98 M | 35.46 M | 34.71 M | 38.75 M | 56.11 M | 53.32 M | 50.03 M | 52.78 M | 67.25 M | 83.08 M | 69.06 M | 74.87 M | 110.55 M | 114.15 M | 82.85 M | 90.82 M | ||||||||||
| Consensus Estimate | 38.95 M | 38.00 M | 36.88 M | 42.96 M | 62.26 M | 57.23 M | 55.54 M | 57.73 M | 74.19 M | 90.82 M | 72.73 M | 80.34 M | 122.55 M | 121.82 M | 86.77 M | 95.32 M |
Analysts expect Ligand Pharmaceuticals Inc to report earnings per share of 2.25 for Q3 26, against a range of 2.14 to 2.36. The most recent reported quarter, Q2 26, came in at 2.37, a 13.9% beat against the 2.08 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 1.84 | 1.27 | 1.33 | 1.60 | 3.09 | 2.02 | 1.63 | 2.37 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 1.37 | 1.21 | 1.22 | 1.53 | 1.99 | 1.56 | 1.93 | 2.23 | 2.36 | 3.34 | 2.55 | 2.66 | 3.68 | 3.99 | 2.90 | 3.29 | ||||||||||
| Low Estimate | 1.21 | 1.05 | 1.12 | 1.39 | 1.79 | 1.30 | 1.63 | 1.93 | 2.14 | 2.82 | 2.27 | 2.42 | 3.30 | 3.69 | 2.46 | 3.07 | ||||||||||
| Consensus Estimate | 1.29 | 1.13 | 1.17 | 1.46 | 1.89 | 1.43 | 1.78 | 2.08 | 2.25 | 3.08 | 2.41 | 2.54 | 3.49 | 3.84 | 2.68 | 3.18 |
Pull Wall Street consensus for Ligand Pharmaceuticals Inc (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=LGND&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "LGND", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=LGND&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();